Downloadable expert content covering integrated, tailored solutions to accelerate your path to market.
How pre-clinical work is driving rapid evaluation of how we strategize to improve efficacy and reduce toxicity towards better therapeutic outcomes.
Learn more about cell line development, upstream process development and process scale-up for SMARTag® technology antibody programs.
Learn how the growing need for partners who can provide niche technologies to accelerate development projects.
Unique biologics solutions and technologies to help develop market-leading products.
Synergistic clonal and process screen to identify master cell bank candidates
As the Biopharma market evolves, the demand increases for bioprocess technologies.
Effective outsourcing strategies and demonstrating how these can be effective through a case study.
Explore the latest biopharma facility investment trends.
Achieve a faster assessment of monoclonal antibody functionality—well before the final molecule is selected.
Biomanufacturing strategies & integrated approach on improving and de-risking lead selection.
Strategies to drive biologics development programs & meet aggressive development timelines.
Cell development and process scale-up for an antibody program with additional processing.
Insights into the new generation of antibody drug conjugates
Obtain consistent highly pure products, lower manufacturing costs & improve process efficiency.
Address challenges in developing biologics and identify keys to succeed in this dynamic space.
Enable precise, programmable, site-selective chemical protein modifications to develop ADCs.
Apply the right clinical supply model based on the nature of the study.
Defining the challenges with manufacturing ADCs and how the market is evolving.
Explore theories and strategies used to build successful antibody-drug conjugates designs.
Supplementing cell culture media with copper can reach high yields of highly converted protein.
Explore the challenges with delivering drugs less invasively.
Successfully develop biological therapeutics within an aggressive program timeline.
Boost bioavailability, improve ease & route of administration, and increase patient compliance.
Address unique program requirements with flexible manufacturing solutions.
Identify new technologies and research resources to navigate emerging trends.
Increase the dissolution rates of poorly water-soluble drugs to increase bioavailability.
Explore new drug development tools to optimize Animal Health products.
Utilize the right APAC packing & distribution network to start studies on time & reduce cost.
Increase patient adherence while reducing reformulation time & costs.
Develop & optimize a logical sourcing strategy in the Asia Pac Region.
Identify most suitable drug delivery technology at early stage of drug development.
Provide the ability to taste mask & coat smaller particle size APIs.
Utilize an all-encompassing approach to enable an effective dosage form faster to market.
Single unit granule formulation allows for high drug load & broad taste-masking techniques.
Implement QbD for inhalation product development to ensure drug and device efficacy and safety.
Enable the formulation development of a drug molecule in softgels on industrial scale machines.
Determine the best clinical supply model to reduce risk and improve performance.
Improve product performance & enhance consumer experience with enteric coating.
Meet the high demands of all natural products with innovative dosage form solutions.
Increase chances of success in drug development by focusing on API optimization from the start.
Successfully launch & develop specific requirements for small molecules, like Safinamide.
Suitable path to accelerate development, avoid risk at early phase & enhance bioavailability.
The rise of Krill Oil education, versatile benefits and consumer acceptance.
Successfully complete multiregional clinical trials (MRCT).
Prevent, treat or manage existing conditions to improve aging consumer's quality of life.
Select the most suitable formulation technology to enhance the molecule’s bioavailability.
The future of non-invasive delivery technologies for large molecules.
Deliver products successfully & economically to emerging markets.
Overcome therapeutic challenges and be prepared for years to come.
Manage a Clinical Supply Chain that is flexibe, traceable, & compliant.
Mitigate risk and drive towards safe and effective drug manufacturing.
Overcome ADC development challenges & improve efficacy and safety.
Generate physically stable & processable amorphous forms of APIs.
Transition from preliminary formulation to commercial drug launch, quickly & cost-effectively.
Unique Consumer Health solutions for OTC, Supplements & Beauty.
Deliver more differentiated dietary supplement products, faster to market.
Strategies and tactics to develop new antibody biosmilar products.
Ideal solution for consumers seeking an animalfree alternative to gelatin capsules.
Develop liquid capsule fill formulations that are mitigated to prevent abuse.
Limit individual variability of type I & II systems with adequate choice of composition.
Handle small amounts of API or formulation at the early stages of development.
Reduce the potential for iatrogenic transmission of pathogenic viruses.
Design a safe, effective & stable dosage form, and ensure patient compliance.
Successfully achieve taste-masking while maintaining release characteristics.
Develop oral dosage forms of water-insoluble compounds with amorphous solid dispersions.
Monitor crystalline state of a compound during stability studies.
Integrated, tailored solutions to accelerate your path to market.
Enable expanded biotechnology applications of the aldehyde tag.
Reduce the risks associated with traditional aseptic manufacturing.
Deliver compliance and flexibility with a convenient, enjoyable dose form.
Improve compatibility with wider range of excipients to enhance bioavailability & stability.
Risk management to reduce the potential for iatrogenic transmission of pathogenic viruses.
Ease of administration to achieve long-term patient compliance & optimal therapeutic outcomes.
Lipid-based drug-delivery systems to assist in the delivery of poorly soluble drugs.
Reduce supply-related risks related to biosimilar product availability, cost & quality.
Perform dosage form selection in the early phases of drug development.
Chewable technology that is ideal to deliver active ingredients, without the need for water.
Potent compound handling to ensure success for complex & possibly dangerous HPAPIs.
Advanced technology platforms to enhance many biotherapeutics including ADCs.
Generating uniform site-specific ADCs utilizing a chemoenzymatic approach.
Offer new preferred benefits and improved efficacy to achieve differentiation.
Ways of increasing ADC stability and efficacy are still required for these therapies.
Optimize manufacturing parameters like lower processing temperature & thinner softgel shell.
Complex, specialized requirements in micronization, to handle the toughest specifications.
Advanced aseptic glass-free delivery solution for injectable treatments.
The toolkit of technologies based upon lipid-based drug delivery systems.
The cytotoxicity of HPAPIs presents handling challenges.
Choose the right technology to develop an efficient Phase I enabling drug product
Drug delivery solutions need to become more sophisticated and more effective.
in OptiMelt™ Hot Melt Extrudates for Development of Stable Final Dosage Forms
Prepared by OptiMelt™ Hot Melt Extrusion for Optimized Oral Solid Dosage Forms
One such technology that minimizes the risk in biologics processing is ADVASEPT® technology.
An appropriate formulation often requires significant API material.
Solubility screening approaches that can save both time and money.
Proven and versatile particle size reduction, micronization and milling technologies
Deliver higher API concentrations in smaller capsules for patient benefits.
OptiPact™ Technology, capabilities for Orphan Drugs & Catalent's factors of differentiation.
Reduce the struggle to administer medication to animal populations.
Overcome dose acceptance and therapeutic compliance hurdles.
Macromolecule delivery by targeted delivery and enteric coating techniques.
BASF & Catalent experts discuss the development of HME oral solid dosage forms.
Macromolecules can potentially be converted from injectable to oral drug delivery.
A proven solution for improving physical stability of many oral formulations.
Discover what constitutes an Advanced Asceptic Process and the numerous advantageous.
The path to successfully marketing a biosimilar product and global regulatory environment.
Switching from small to large molecules in pharma, cell line expression and emerging markets.
The future of site-specific conjugation to improve CMC production and therapeutic index.
Innovative oral softgel platform capable of delivering multiple actives.
Learn the fundamentals of the advanced aseptic process utilizing BFS technology.
Learn about how softgel technologies can address API and processing challenges.
Learn more about integrating formulation technology in drug development.
Learn about two major changes to the USP pertaining to <231> & <661>.
BFS technology has been expanding into injectables and into biologics.
Graduate students in pharmaceutical sciences provide commentary on drug delivery topics.
Developing orphan drugs to treat rare diseases is an industry priority.
How integrated development programs can be used to mitigate risk and reduce timelines.
New technology enables a brand to keep its leading market position.
RP Scherer Technology can improve timelines and commercialization potential.
Insights in order to eliminate risk inherent to sterile manufacturing environments.
Catalent is using rational conjugate design with selective drug placement.
Learn about Orphan drug development and other fast track product development pathways.
Compatibility of model mAb formulation in glass and Advasept® Vials.
Development of a single process configuration that reduces cost and decreases time.
This project was aimed to develop and fully validate an UPLC method.
This on-demand webinar will identify ways to determine the ideal formulation for your molecule
Bioconjugates show great promise to improve existing therapeutics.
Learn more about the challenge of continuous supply available to meet clinical study needs,
Commercial success of a drug can be influenced by patient’s perception of the formulation.
Catalent worked with the client to bring a vastly superior sublingual product to market.
Creation of a custom packaging/distribution concept to meet the client’s needs.
Identification of the impurities combined with analytical and sample handling challenges.
Case study describing custom batch manufacture of the product at a reasonable cost.
Catalent's OptiGel® Bio technology can provide a pathway for an IV to oral delivery conversion.
Patient compliance with medication can be especially challenging for pediatric populations.
Extractable and leachable detection methods and best practices.
The first-ever survey investigating patient experiences with clinical trial materials
A detailed understanding of the material science of the tablet structure
Innovative biotechnology company exploring therapeutics for neuroscience indications
How Clinical Supply Management Systems can bring efficiencies to support Project Lifecycle
Global manufacturers are exploring the possibility of producing biosimilars
In today's enviroment solution providers are preferred over CMO's.
CMOs share their opinions on the prospects for their businesses.
An interview with Catalent's Scott Houlton.
Specialized analytical and formulation tools aid in successful, timely Development of LBDDS.
Key considerations for selection, benefits, limitations, and future prospects.
Bend Research and Catalent enter into an agreement to provide integrated solutions.
This webcast will highlight the latest omega-3 drug developments.
This article explores importing clinical trial materials to South America.
Catalent expert Mike Jenkins explains the change Catalent's facility is making.
Explore recent advances in regards to tablet technologies.
Catalent expert interviewed at INTERPHEX 2011 about the blow/fill/seal process.
A comparison between GPEx® and traditional cell line engineering technology.
This article looks into current problems in assuring virological safety of biopharmaceuticals.
Providing a definition for virus safety is nebulous at best.
Catalent expert, Mike Merges, explores practical considerations for bioassays.
Project management is becoming more important as companies increase outsourcing.
Explore overcoming challenges in the tech transfer of biopharma products.
Catalent expert discusses how Catalent is becoming a one-stop shop for global customers.
Removal of impurities is critical in the purification process for production of final products.
Integrating quality by design into sterile manufacturing facilities is becoming more important.
Learn about how talent and technology can help grow a company.
This presentation focuses on improving oral delivery for poorly soluble/permeable drugs.
Absence of evidence is not evidence of absence.
Explore the issues with technical transfer in regardss to complex pharmaceutical products
Because of the growing significance of specialty polymers, a need to fully characterize these materials for structure and purity has emerged.
Investigate the relationship between poorly-soluble drugs and disintegration time of (ODTs)
Evaluate the pharmacokinetic behavior of nanosized fenofibrate administered orally
Disintegration and dissolution characteristics of novel, polysaccharidebased shell softgels
Determination of elemental impurities in support of USP <232> and <233>
Development and validation of a method for determination of bismuth
From formulation to specialty packaging, this article explores patient adherence.
Explore the power of dual detection methods to identify impurties.
An overview of stability studies during drug product lifecycles.
New data shows drug delivery has a positive impact on patient compliance.
This presentation details a case study about a phase III global trial.
VP of Corporate Strategy and Development discusses emerging drug-delivery technologies.
This presentation deals with the challenges of using suppliers from around the globe
Catalent executive discusses excellence in compliance in Pharmaceutical Formulation & Quality
As the use of “universal” HPLC detectors and charged aerosol detectors become more common
Discussion around the latest trends and issues involving solubility.
Advances in medical discoveries are for nothing if the medicine isn't taken.
Focuses on new innovation drug delivery devices for patient-administered therapies
Catelent CEO John Chiminski discusses our offerings
New study shows superior patient compliance with oral fast dissolve delivery.
Presentation on ensuring viological safety of biologicals
Exploration of the largest trends in the prefilled syringe and autoinjection devices
Prefilled Syringes Pinpoint Stability, Compatability, and Safety
‘Lean’ is a familiar term in European manufacturing since markets are more competitive
New strategies in formulation development are helping overcome molecule challenges
Softgel Technology as a Lipid-Based Delivery Tool for Bioavailability Enhancement
The aseptic blow-fill-seal (B/F/S) systems have experienced growth.
Case Study: Marchesini Group for Catalent Pharma Solutions: Efficient Syringe Packaging
Catalent experts talk about the increasing demand of prefilled syringes
Presentation detailing inhaled products as well as emerging technologies in this area
Clinical trials are a critical step in the approval process for new drugs.
Peptides can counteract many mechanisms of aging that were not possible to address in the past. Check out their possible capabilities.
Selection of a solid-state form is an important decision in development of small molecule API's
VP of business development discusses blow/fill/seal market and offerings
Fish gelatin support of nanoparticle formation of poorly water-solubles during wet milling
The striking efficiency gains Catalent has achieved with the Lean System for Managing
Modern healthcare challenges and predictions for pharmaceutical market growth
General review of Catalent’s new technology that optimizes API and profitability
Validate method for determination of extractable & leachable silicone oil
Effect of a Kollicoat Top-coat on the physical stability of enteric-coated softgels
Study on the impact of emulsion liposomal liquid and lyophilized liposomal formulations.
Why oral disintegrating tablets are so important to the industry’s oral dose form kit
How manufacturers can partner with contract packagers in new and increasingly complex ways
Explore a cGMP manufacturing model for reducing operating costs and speeding up drugs to market
Pros and cons of options, plus discussion of global problems and lack of foreign security
Laser diffraction particle size analysis – a robust and efficient alternative
Development procedures to reduce antibody effect on Protein Z, with validation results
Study shows import plasticizer level, & potential for migration from coating to shell
Determination of residual solvents in API by headspace GC-MS needs multiple analyses
Implications of FDA release and responsive technologies available to the manufacturer
The more efficient a bioassay method transfer, the faster to regulatory submission
Approach to validate from preclinical development to final commercial implementation
Rapid development model for formulation feasibility & accelerated stability evaluation
Method to separate un-derivatized protein Z (uTPZ) from derivatized TPZ in 3 species
Validate responsive ELISA for the detection of IPZ in monkey, rat, and human serum fluid
Robust options available for micro-dosing inhalation powders with some important caveats
Study investigates design using synthetic molecule recognizing immunoglobulin in serums
Novel approach to validate a method for the determination of water content
New shell and hot-filling that are highly viscous or semi-solid at room temperature
Proven, acceptable NMR spectroscopy test for common EMAs in raw materials and APIs